References
- Abd El-Haleim EA, Bahgat AK, Saleh S. (2016). Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: modulation of gene expression. Eur J Pharmacol 773:59–70
- Agarwal S, Yadav A, Chaturvedi RK. (2017). Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders. Biochem Biophys Res Commun 483:1166–77
- Berger J, Leibowitz MD, Doebber TW, et al. (1999). Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 274:6718–25
- Bu HZ, Magis L, Knuth K, Teitelbaum P. (2001). High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Commun Mass Spectrom 15:741–8
- Chiang MC, Nicol CJ, Cheng YC, et al. (2016). Rosiglitazone activation of PPARγ-dependent pathways is neuroprotective in human neural stem cells against amyloid-beta-induced mitochondrial dysfunction and oxidative stress. Neurobiol Aging 40:181–90
- Draft Guidance for Industry, Drug Interaction Studies—Study Design, Data Analysis, and Implications for Dosing and Labeling, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Sep 2006
- Fan PW, Song Y, Berezhkovskiy LM, et al. (2014). Practical permeability-based hepatic clearance classification system (HepCCS) in drug discovery. Future Med Chem 6:1995–2012
- Fredlund L, Winiwarter S, Hilgendorf C. (2017). In vitro intrinsic permeability: a transporter-independent measure of Caco-2 cell permeability in drug design and development. Mol Pharm 14:1601–9
- Giri P, Naidu S, Patel N, et al. (2017). Evaluation of in vitro cytochrome P450 inhibition and in vitro fate of structurally diverse N-oxide metabolites: case studies with clozapine, levofloxacin, roflumilast, voriconazole and zopiclone. Eur J Drug Metab Pharmacokinet 42:677–88
- Jain MR, Giri S, Trivedi C, et al. (2015). Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin sensitizing effect in preclinical model. Pharmacol Res Perspect 3:e00136
- Jani RH, Kansagra K, Jain MR, Patel H. (2013). Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects. Clin Drug Investig 33:809–16
- Lu C, Li P, Gallegos R, et al. (2006). Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 34:1600–5
- Massaro M, Scoditti E, Pellegrino M, et al. (2016). Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes. Pharmacol Res 107:125–36
- Patel MR, Kansagra KA, Parikh DP, et al. (2017). Effect of food on the pharmacokinetics of saroglitazar magnesium, a novel dual PPARα/γ agonist, in healthy adult subjects. Clin Drug Investig. [Epub ahead of print]. DOI: 10.1007/s40261-017-0584-2
- Richardson SJ, Bai A, Kulkarni AA, Moghaddam MF. (2016). Efficiency in drug discovery: liver S9 Fraction assay as a screen for metabolic stability. Drug Metab Lett 10:83–90
- Srinivas NR, Mullangi R. (2015). Bioanalysis in oncology drug discovery. Biomark Med 9:877–86
- Zhu YX, Zhang ML, Zhong Y, et al. (2016). Modulation effect of peroxisome proliferator-activated receptor agonists on lipid droplet proteins in liver. J Diabetes Res 2016:8315454